Indaptus Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Indaptus Therapeutics, Inc. (INDP) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$368.40 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$249.09K.
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$119.32K.
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$203.39K, a 128.39% decline year-over-year.
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $358.00K, a 477.31% increase year-over-year.
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$667.29K, a 914.32% decline from fiscal 2024.
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $81.94K.
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$161.80K.
- Indaptus Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$295.22K, a 135.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$249.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$368.40K 10-Q · filed 2026-08-13 | -$571.79K derived: sum of 3 quarters · filed 2026-08-13 | -$213.79K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$119.32K 10-Q · filed 2026-05-15 | -$322.70K derived: sum of 2 quarters · filed 2026-05-15 | $35.29K derived: sum of 3 quarters · filed 2026-05-15 | -$779.26K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$203.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $154.61K derived: sum of 2 quarters · filed 2026-03-17 | -$659.94K derived: sum of 3 quarters · filed 2026-08-13 | -$667.29K 10-K · filed 2026-03-17 |
| 2025-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$456.56K derived: sum of 2 quarters · filed 2026-08-13 | -$463.90K 10-Q · filed 2025-11-12 | $252.46K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$814.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$821.90K 10-Q · filed 2026-08-13 | -$105.54K derived: sum of 3 quarters · filed 2026-08-13 | -$43.52K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$7.35K 10-Q · filed 2026-05-15 | $709.02K derived: sum of 2 quarters · filed 2026-05-15 | $771.03K derived: sum of 3 quarters · filed 2026-05-15 | $406.72K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $716.36K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $778.37K derived: sum of 2 quarters · filed 2026-03-17 | $414.07K derived: sum of 3 quarters · filed 2026-03-17 | $81.94K 10-K · filed 2026-03-17 |
| 2024-09-30 | $62.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$302.29K derived: sum of 2 quarters · filed 2025-11-12 | -$634.42K 10-Q · filed 2025-11-12 | -$880.79K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$364.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$696.43K 10-Q · filed 2025-08-13 | -$942.80K derived: sum of 3 quarters · filed 2025-08-13 | -$244.06K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$332.13K 10-Q · filed 2025-05-14 | -$578.49K derived: sum of 2 quarters · filed 2025-05-14 | $120.25K derived: sum of 3 quarters · filed 2025-05-14 | -$169.72K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$246.37K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $452.37K derived: sum of 2 quarters · filed 2025-03-13 | $162.41K derived: sum of 3 quarters · filed 2025-03-13 | -$161.80K 10-K · filed 2025-03-13 |
| 2023-09-30 | $698.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $408.77K derived: sum of 2 quarters · filed 2024-11-12 | $84.57K 10-Q · filed 2024-11-12 | -$237.39K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$289.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$614.17K 10-Q · filed 2024-08-12 | -$936.13K derived: sum of 3 quarters · filed 2024-08-12 | -$63.62K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$324.20K 10-Q · filed 2024-05-08 | -$646.16K derived: sum of 2 quarters · filed 2024-05-08 | $226.34K derived: sum of 3 quarters · filed 2024-05-08 | -$254.72K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$321.96K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $550.55K derived: sum of 2 quarters · filed 2024-03-13 | $69.49K derived: sum of 3 quarters · filed 2024-03-13 | -$295.22K 10-K · filed 2024-03-13 |
| 2022-09-30 | $872.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $391.45K derived: sum of 2 quarters · filed 2023-11-06 | $26.74K 10-Q · filed 2023-11-06 | -$264.28K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$481.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$845.77K 10-Q · filed 2023-08-14 | -$1.14M derived: sum of 3 quarters · filed 2023-08-14 | -$39.21K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$364.71K 10-Q · filed 2023-05-11 | -$655.72K derived: sum of 2 quarters · filed 2023-05-11 | $441.85K derived: sum of 3 quarters · filed 2023-05-11 | $363.33K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$291.02K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $806.56K derived: sum of 2 quarters · filed 2023-03-17 | $728.03K derived: sum of 3 quarters · filed 2023-03-17 | $837.92K 10-K · filed 2023-03-17 |
| 2021-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.02M derived: sum of 2 quarters · filed 2022-11-10 | $1.13M 10-Q · filed 2022-11-10 | $1.11M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$78.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $31.36K 10-Q · filed 2022-08-08 | $9.13K derived: sum of 3 quarters · filed 2022-08-08 | |
| 2021-03-31 | $109.88K 10-Q · filed 2022-05-12 | $87.65K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$22.23K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$2.81K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $19.42K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |